SLCO1A2 and ovarian serous adenocarcinoma: In contrast, the SLCO1A2, SLCO1B1, SLCO1B3, SLCO1C1, SLCO2B1, and SLCO4A1 genes were amplified in 4.7–7.4% of a total of 316 patients with serous ovarian cancer, with concurrent amplification of SLCO1A2/1B1/1B3/1C1 and SLCO1B1/1B3/1C1, and also SLCO1B3/1C1.